ATE516345T1 - Von ibdv (infectious bursal disease virus) abgeleitete chimäre leere virusähnliche partikel, verfahren zu deren herstellung und anwendungen - Google Patents

Von ibdv (infectious bursal disease virus) abgeleitete chimäre leere virusähnliche partikel, verfahren zu deren herstellung und anwendungen

Info

Publication number
ATE516345T1
ATE516345T1 AT06762595T AT06762595T ATE516345T1 AT E516345 T1 ATE516345 T1 AT E516345T1 AT 06762595 T AT06762595 T AT 06762595T AT 06762595 T AT06762595 T AT 06762595T AT E516345 T1 ATE516345 T1 AT E516345T1
Authority
AT
Austria
Prior art keywords
ibdv
virus
particles
bursal disease
infectious bursal
Prior art date
Application number
AT06762595T
Other languages
German (de)
English (en)
Inventor
Aguirre Jose Francisco Ctro Rodroeguez
Castan Jose Ruiz
Gamez Irene Saugar
Blanco Ana Maria Ona
Fern Ndez-Alba Juan Ramon Rodroeguez
Original Assignee
Consejo Superior Investigacion
Bionostra S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior Investigacion, Bionostra S L filed Critical Consejo Superior Investigacion
Application granted granted Critical
Publication of ATE516345T1 publication Critical patent/ATE516345T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10023—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT06762595T 2005-07-15 2006-07-14 Von ibdv (infectious bursal disease virus) abgeleitete chimäre leere virusähnliche partikel, verfahren zu deren herstellung und anwendungen ATE516345T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200501733A ES2310062B1 (es) 2005-07-15 2005-07-15 Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
PCT/EP2006/006915 WO2007009673A1 (en) 2005-07-15 2006-07-14 Chimeric empty viral-like particles derived from the infectious bursal disease virus (ibdv), process for their production and applications

Publications (1)

Publication Number Publication Date
ATE516345T1 true ATE516345T1 (de) 2011-07-15

Family

ID=37662111

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06762595T ATE516345T1 (de) 2005-07-15 2006-07-14 Von ibdv (infectious bursal disease virus) abgeleitete chimäre leere virusähnliche partikel, verfahren zu deren herstellung und anwendungen

Country Status (9)

Country Link
US (1) US7476387B2 (enExample)
EP (1) EP1904626B1 (enExample)
JP (1) JP5713533B2 (enExample)
CN (1) CN101278043A (enExample)
AT (1) ATE516345T1 (enExample)
AU (1) AU2006271978B2 (enExample)
CA (1) CA2615468C (enExample)
ES (2) ES2310062B1 (enExample)
WO (1) WO2007009673A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2093281A1 (en) * 2008-02-19 2009-08-26 Kapsid Link, S.L. Protein nanocarriers, process for obtaining them and applications
EP2288618B1 (en) * 2008-05-09 2017-09-20 Chimera Pharma S.l.u. Chimeric fusion proteins and virus like particles from birnavirus vp2
WO2011054995A2 (es) 2009-11-06 2011-05-12 Chimera Pharma, S. L. U. VACUNAS PROFILACTICAS DE GRIPE A PARTIR DE CAPSIDAS VIRALES DE BIRNAVIRUS CONTENIENDO EL ANTIGENO M2e DEL VIRUS DE LA GRIPE
JP5795319B2 (ja) * 2009-11-06 2015-10-14 チャイメラ ファーマ エス．エル．ユー．Ｃｈｉｍｅｒａ Ｐｈａｒｍａ Ｓ．Ｌ．Ｕ． ヒトパピローマウイルス抗原を含むビルナウイルスのウイルスカプシドに基づく腫瘍形成を処置するためのワクチン
CN104093420B (zh) 2011-11-03 2017-07-28 森提耐斯特治疗公司 针对人肠道病毒的抗原及疫苗
WO2014008475A2 (en) 2012-07-05 2014-01-09 The Ohio State University Compositions and methods related to viral vaccines
US10086062B2 (en) 2012-07-05 2018-10-02 Ohio State Innovation Foundation Infectious pancreatic necrosis virus (IPNV) vaccine compositions
EP3089755A1 (en) * 2014-01-03 2016-11-09 Fundacion Biofisica Bizkaia VLPs, METHODS FOR THEIR OBTENTION AND APPLICATIONS THEREOF
CN107034198B (zh) * 2015-07-15 2021-03-09 长春百克生物科技股份公司 一种嵌合诺如病毒p颗粒及其制备和应用
CN108624611A (zh) * 2018-05-15 2018-10-09 武汉科前生物股份有限公司 传染性法氏囊病毒病毒样颗粒的制备及其应用
WO2023062182A1 (en) * 2021-10-15 2023-04-20 Aquilón Cyl, S.L. Vaccine compositions against bovine viral diarrhea virus
CN114058524A (zh) * 2021-10-28 2022-02-18 复旦大学 一种法氏囊亚病毒颗粒疫苗及其制备方法

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0174444B1 (en) 1984-06-18 1992-03-11 Chiron Corporation Hepatitis surface antigen particle vaccine
US5614409A (en) 1989-05-30 1997-03-25 Commonwealth Scientific And Industrial Research Organisation Production of IBDV VP2 in highly immunogenic form
US5641490A (en) 1991-03-07 1997-06-24 Virogenetics Corporation Infectious bursal disease virus recombinant poxvirus vaccine
WO1992022575A1 (en) 1991-06-19 1992-12-23 Sri International M-protein peptides of influenza virus as antiviral agents
JPH06509235A (ja) 1991-07-26 1994-10-20 ヴァイロジェネティクス　コーポレイション 伝染性ファブリキウス嚢病ウイルス組換えポックスウイルスワクチン
US5658572A (en) 1991-07-26 1997-08-19 Virogenetics Corporation Infectious bursal disease virus recombinant poxvirus vaccine
US5290686A (en) 1991-07-31 1994-03-01 The United States Of America As Represented By The Department Of Health And Human Services Expression of influenza a M2 protein in baculovirus
JPH05194597A (ja) 1991-12-20 1993-08-03 Nippon Seibutsu Kagaku Kenkyusho 防御抗原性を有する伝染性ファブリキウス嚢病ウイルス（ｉｂｄｖ）の粒子製造法
US5605792A (en) 1993-11-04 1997-02-25 The Ohio State University Research Foundation Infectious bursal disease virus VP2 fusion protein expressed by baculovirus, use as diagnostic
US5788970A (en) 1994-03-29 1998-08-04 The University Of Maryland College Park Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon
AT402898B (de) 1994-08-08 1997-09-25 Int Centre Genetic Eng & Bio Molekulares präsentiersystem
ES2282998T3 (es) 1996-01-02 2007-10-16 Institut Pasteur Pseudo-particularmente viricas recombinadas y aplicaciomnes vacunales y antitumorales.
US5871744A (en) 1996-09-05 1999-02-16 University Of Maryland-Biotechnology Inst. Method for generating birnavirus from synthetic RNA transcripts
US5916879A (en) 1996-11-12 1999-06-29 St. Jude Children's Research Hospital DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof
EP0861665A1 (en) 1997-02-03 1998-09-02 Dimminaco Ag/Sa/Ltd. Infectious bursitis vaccine
AU750702B2 (en) 1997-05-01 2002-07-25 Chiron Corporation Use of virus-like particles as adjuvants
CA2238659C (en) 1997-05-26 2010-12-14 Akzo Nobel N.V. Recombinant birnavirus vaccine
EP0887412B1 (en) 1997-05-26 2003-10-15 Akzo Nobel N.V. Recombinant birnavirus vaccine
US6596280B1 (en) 1997-07-31 2003-07-22 University Of Maryland Biotechnology Institute Method for generating birnavirus from synthetic RNA transcripts
US6169175B1 (en) 1997-08-06 2001-01-02 Centers For Disease Control And Prevention Preparation and use of recombinant influenza A virus M2 construct vaccines
US6231868B1 (en) 1997-09-30 2001-05-15 University Of Maryland-Biotechnology Institute Method for generating nonpathogenic infections birnavirus from synthetic RNA transcripts
US6171591B1 (en) 1997-12-08 2001-01-09 Pentamer Pharmaceuticals, Inc. Recombinant nodavirus compositions and methods
US6406843B1 (en) 1998-02-27 2002-06-18 University Of Arkansas Poultry virus isolates and method
WO1999050419A2 (en) 1998-03-31 1999-10-07 University Of Maryland Biotechnology Institute A method for generating nonpathogenic, infectious pancreatic necrosis virus (ipnv) from synthetic rna transcripts
US6114112A (en) 1998-05-21 2000-09-05 The Ohio State University Method of making immunogenic compositions for infectious bursal disease virus
AU770802B2 (en) * 1998-10-21 2004-03-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Virus-like particles for the induction of autoantibodies
HUP9802974A1 (hu) 1998-12-19 2000-09-28 Mezőgazdasági Biotechnológiai Kutatóközpont Fertőző bursitis elleni DNS-vakcina
EP1980617A1 (en) 1998-12-31 2008-10-15 Novartis Vaccines and Diagnostics, Inc. Improved expression of HIV polypeptides and production of virus-like particles
US6528063B2 (en) * 1999-01-04 2003-03-04 Rahan Meristem Recombinant vaccines against IBDV
EP1069187A1 (en) 1999-07-14 2001-01-17 Stichting Dienst Landbouwkundig Onderzoek Mosaic Infectious Bursal Disease Virus vaccines
FR2806087B1 (fr) 2000-03-07 2002-10-18 Agronomique Inst Nat Rech Particules pseudovirales de rotavirus et leur utilisation pour vectoriser des proteines ou des acides nucleiques
AU5533601A (en) 2000-04-14 2001-10-30 Wisconsin Alumni Res Found Viruses comprising mutation ion channel protein
US20020165176A1 (en) 2000-05-01 2002-11-07 Haynes Joel R. Nucleic acid immunization
AU2001252458A1 (en) * 2000-05-05 2001-11-20 Martin Bachmann Molecular antigen arrays and vaccines
WO2001097839A1 (en) 2000-06-19 2001-12-27 Rahan Meristem Recombinant vaccines against infectious bursal disease virus
EP1294892B1 (en) 2000-06-23 2007-10-17 Wyeth Holdings Corporation Assembly of wild-type and chimeric influenza virus-like particles (vlps)
AU2002211999A1 (en) * 2000-10-02 2002-04-15 Id Biomedical Corporation Haemophilus influenzae antigens and corresponding DNA fragments
ATE433491T1 (de) 2001-01-18 2009-06-15 Vlaams Interuniv Inst Biotech Oligomerische komplexe von chimären proteinen mit verbessertem immunogenen potential
FR2824327B1 (fr) * 2001-05-02 2003-07-11 Agronomique Inst Nat Rech Particules pseudovirales de birnavirus
WO2002096940A2 (en) 2001-05-31 2002-12-05 Id-Lelystad, Institut Voor Dierhouderij En Diergezondheid B.V. Attenuated very virulent infectious bursal disease virus
US6936256B2 (en) 2001-08-10 2005-08-30 University Of Maryland Biotechnology Institute Sub-unit vaccine for infectious pancreatic necrosis virus
AUPR721101A0 (en) * 2001-08-23 2001-09-13 University Of Queensland, The Nucleic acid and polypeptide linked to breast cancer
ATE447967T1 (de) 2001-09-14 2009-11-15 Cytos Biotechnology Ag Verpackung von immunstimulierendem cpg in virusähnlichen partikeln: herstellungsverfahren und verwendung
EP1425040A2 (en) 2001-09-14 2004-06-09 Cytos Biotechnology AG In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
US6764684B2 (en) 2001-09-28 2004-07-20 Zeon Corporation Avian herpesvirus-based recombinant infectious bursal disease vaccine
JP2005535287A (ja) * 2002-02-11 2005-11-24 アイディー バイオメディカル コーポレイション グループｂ連鎖球菌抗原
WO2003074552A1 (en) 2002-03-01 2003-09-12 Akzo Nobel N.V. An infectious bursal disease virus variant
PT1506222E (pt) 2002-05-17 2009-06-12 Univ Cape Town Proteínas l1 quiméricas do papilomavírus humano 16 incluindo um péptido l2, partículas semelhantes a vírus preparadas a partir daquelas e um método de preparação das partículas
ATE489969T1 (de) 2002-06-20 2010-12-15 Cytos Biotechnology Ag Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung
CA2490866A1 (en) 2002-06-26 2004-01-08 Advanced Bionutrition Corporation Viruses and virus-like particles for multiple antigen and target display
RU2324704C2 (ru) 2002-07-17 2008-05-20 Цитос Байотекнолоджи Аг Молекулярные массивы антигенов
WO2004025263A2 (en) 2002-09-16 2004-03-25 Advanced Bionutrition Corporation Protein and peptide expression for passive immunity
MXPA05009580A (es) 2003-03-07 2005-10-19 Merck & Co Inc Vacuna contra el virus de la influenza.
ES2217967B1 (es) 2003-03-31 2006-01-01 Consejo Sup. Investig. Cientificas Procedimiento de produccion de particulas virales vacias (vlps) del virus inductor de la bursitis infecciosa (ibdv), composiciones necesarias para su puesta a punto y su uso en la elaboracion de vacunas frente al ibdv.
JP5215561B2 (ja) 2003-05-28 2013-06-19 ウィスコンシン アルムニ リサーチ ファンデイション ワクチン及び遺伝子治療のための高力価組換えインフルエンザ・ウイルス
CA2527102A1 (en) 2003-07-10 2005-01-20 Cytos Biotechnology Ag Packaged virus-like particles
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
EP1689858B1 (en) 2003-11-13 2013-05-15 University Of Georgia Research Foundation, Inc. Methods of characterizing infectious bursal disease virus
ES2307345B1 (es) 2004-01-21 2009-11-13 Consejo Sup. Investig. Cientificas Capsidas vacias quimericas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
ES2307346B1 (es) 2004-01-21 2009-11-13 Consejo Sup. Investig. Cientificas Capsidas vacias (vlps(-vp4)) del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
ES2242542B1 (es) 2004-04-30 2006-12-16 Consejo Superior De Investigaciones Cientificas Procedimiento para la produccion en levaduras de capsidas virales vacias compuestas por proteinas derivadas de pvp2 del virus causante de la enfermedad de la bursitis infecciosa (ibdv).
AU2005248361B2 (en) 2004-05-18 2010-03-11 Vical Incorporated Influenza virus vaccine composition and methods of use
EP2578229B1 (en) 2004-09-09 2013-07-10 Novartis Vaccines and Diagnostics GmbH Decreasing potential iatrogenic risks associated with vaccine antigens
BRPI0516953A (pt) 2004-09-21 2008-09-30 Cytos Biotechnology Ag partìculas do tipo vìrus compreendendo uma proteìna de fusão da proteìna de revestimento de ap205 e um polipeptìdeo antigênico
US7244432B2 (en) 2004-12-08 2007-07-17 University Of Maryland Biotechnology Institute Infectious bursal disease virus (IBDV) variant from Georgia

Also Published As

Publication number Publication date
EP1904626B1 (en) 2011-07-13
ES2371833T3 (es) 2012-01-10
US20070015243A1 (en) 2007-01-18
AU2006271978A1 (en) 2007-01-25
JP2009501012A (ja) 2009-01-15
US7476387B2 (en) 2009-01-13
CA2615468C (en) 2015-04-14
CN101278043A (zh) 2008-10-01
EP1904626A1 (en) 2008-04-02
WO2007009673A1 (en) 2007-01-25
CA2615468A1 (en) 2007-01-25
ES2310062B1 (es) 2009-11-13
ES2310062A1 (es) 2008-12-16
JP5713533B2 (ja) 2015-05-07
AU2006271978B2 (en) 2012-08-02

Similar Documents

Publication Publication Date Title
IL189313A (en) Virus-like particles as virus-paramixo vaccines, a method for their preparation and use
ATE516345T1 (de) Von ibdv (infectious bursal disease virus) abgeleitete chimäre leere virusähnliche partikel, verfahren zu deren herstellung und anwendungen
NZ595736A (en) Chimeric viruses presenting non-native surface proteins and uses thereof
WO2007011904A3 (en) Recombinant flu vaccines
EA200100619A1 (ru) Коровые антигенные частицы hbv с множественными иммуногенными компонентами, связанными посредством пептидных лигандов
WO2002074795A3 (en) Oligomeric complexes of chimeric proteins with enhanced immunogenic potential
AU2016219738A1 (en) Designer peptide-based PCV2 vaccine
WO2008009652A3 (en) Vaccines for malaria
WO2006096459A3 (en) Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof
WO2008148104A8 (en) Novel vlps derived from cells that do not express a viral matrix or core protein
WO2004001051A3 (en) Recombinant measles viruses expressing epitopes pf antigens of rna viruses and use of the recombinant viruses for the preparation of vaccine compositions
NZ741875A (en) Canine parvovirus (cpv) virus-like particle (vlp) vaccines and uses thereof
PL351277A1 (en) Nucleic acid sequence, dna fragments, recombined dna molecules, live recombined carriers, host cells, proteins and their application, vaccines against lawsonia intracellularis and methods of obtaining them as well as relevant diagnostic tests
EP1331271A4 (en) POLYPEPTIDE FRAGMENT OF HEPATITIS E VIRUS, VACCINE COMPOSITION CONTAINING SAID FRAGMENT, DIAGNOSTIC AGENT AND THEIR APPLICATIONS
WO2001021807A8 (en) Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
ATE424450T1 (de) Chimärische leere capside des ibdv (infectious bursal disease virus), gewinnungsverfahren und anwendungen
TW201008576A (en) New fusion proteins and their use for the preparation of vaccines against hepatitis C
MXPA02012593A (es) Particulas de tipo virus del virus de la diarrea viral bovina.
MY207280A (en) Polyvalent immunogenicity composition for human papillomavirus
ATE534666T1 (de) Antikörper gegen den hepatitis c-virus e1e2 komplex und pharmazeutische zusammensetzungen
EA201890187A1 (ru) Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита
RU2007129962A (ru) Универсальная вакцина против вируса гриппа птиц
WO2002088339A3 (fr) Particules pseudovirales de birnavirus
WO2007144886A3 (en) Virus-like particles for treatment of viral infections
WO2020011755A8 (en) Antibodies having specificity for the orf2i protein of hepatitis e virus and uses thereof for diagnostic purposes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties